Nasdaq:KYMR
Kymera Therapeutics, Inc.
A clinical-stage biopharmaceutical firm pioneering small molecule solutions for intrinsically disordered proteins (IDPs) to treat complex diseases.
Key Metrics
Investment Thesis
Bull Case
Investors may buy Kymera stock anticipating that its unique IDP platform will yield breakthrough therapies for currently unmet medical needs, potentially leading to high-margin blockbuster drugs. The company's robust cash position and recent financing activities suggest a strong ability to fund expensive clinical trials without immediate dilution concerns. Success in late-stage trials could transform the business from a cash-burning R&D entity into a profitable commercial pharmaceutical leader.
Bear Case
The stock is risky due to consistently widening net losses, which deepened to -$311.4M in 2025, raising concerns about the sustainability of current burn rates and funding requirements. Revenue volatility and a downward trend from 2023 to 2025 indicate potential struggles in maintaining lucrative partnership agreements or commercializing products effectively. The lack of approved products means the company has no current cash flow from sales, making it entirely dependent on future clinical successes and external capital injections.
About Kymera Therapeutics, Inc.
Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecules that target intrinsically disordered proteins (IDPs), which are implicated in various diseases. The company primarily serves the global pharmaceutical market with its proprietary drug candidates targeting conditions such as neurodegenerative disorders and metabolic diseases. Its revenue streams currently consist of research collaboration agreements and potential future commercialization of approved therapies.
Analysis
Management Discussion
Management has aggressively invested in R&D, spending $316.6M in the latest period compared to $39.2M in revenue, resulting in an operating loss of -$349.4M and a net loss of -$311.4M. While cash flow from operations was negative at -$232.9M, significant capital raised via financing ($990.7M) and asset sales ($488M proceeds) bolstered the balance sheet to $1.74B in total assets. The decline in revenue from 2023 to 2025 suggests challenges in sustaining collaboration income or transitioning to commercial product sales.
Industry Overview
Kymera operates within the highly competitive biopharmaceutical industry, specifically targeting intrinsically disordered proteins (IDPs) which represent a frontier in drug discovery that traditional players often overlook. The sector is characterized by high failure rates in clinical trials, substantial R&D expenditures, and long development timelines before products reach market. Success in this niche depends on scientific validation of the IDP hypothesis and the ability to navigate complex regulatory pathways for novel mechanisms of action.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $46.8M | $78.6M | $47.1M | $39.2M |
| Cost of Revenue | $0 | $0 | $47.1M | $39.2M |
| Gross Profit | $46.8M | $78.6M | $0 | $0 |
| Operating Expenses | $208.1M | $244.1M | $308.7M | $388.6M |
| Operating Income | $-161.3M | $-165.5M | $-261.6M | $-349.4M |
| R&D | $164.2M | $189.1M | $240.2M | $316.6M |
| G&A | $43.8M | $55.0M | $63.5M | $68.2M |
| Stock-Based Comp | $35.5M | $43.1M | $55.0M | $59.9M |
| D&A | $3.0M | $3.6M | $7.4M | $8.3M |
| Depreciation | $3.0M | $3.6M | $7.4M | $8.3M |
| Other OpEx | $0 | $0 | $4.9M | $3.9M |
| Non-Operating Income | $0 | $0 | $0 | $38.0M |
| Interest Income | — | — | $38.0M | $38.4M |
| Pre-Tax Income | $-161.3M | $-165.5M | $-261.6M | $-311.4M |
| Income Tax | $0 | $-18.6M | $-37.8M | $0 |
| Continuing Ops | $-161.3M | $-147.0M | $-223.9M | $-311.4M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-154.8M | $-147.0M | $-223.9M | $-311.4M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-154.8M | $-147.0M | $-223.9M | $-311.4M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $419.4M | $405.3M | $510.3M | $871.2M |
| Cash & Equivalents | $68.4M | $110.0M | $120.3M | $357.0M |
| Accounts Receivable | — | $15.0M | $0 | — |
| Prepaid Expenses | $9.7M | $11.7M | $20.6M | $22.9M |
| Other Current Assets | $341.3M | $268.7M | $369.4M | $491.3M |
| Long-Term Assets | $183.7M | $170.4M | $467.8M | $871.6M |
| PP&E (Net) | $13.3M | $48.1M | $50.5M | $43.2M |
| Operating Leases | $8.9M | $52.9M | $47.4M | $42.4M |
| Other LT Assets | $161.5M | $69.4M | $369.9M | $786.1M |
| Total Assets | $603.1M | $575.8M | $978.0M | $1.74B |
| Current Liabilities | $71.3M | $85.7M | $67.8M | $83.2M |
| Accounts Payable | $4.3M | $7.1M | $6.0M | $4.0M |
| Current Leases | $2.5M | $5.1M | $11.6M | $11.9M |
| Deferred Revenue | $35.3M | $37.9M | $13.6M | $22.9M |
| Other Current Liab | $1.7M | $1.8M | $1.7M | $2.1M |
| Long-Term Liabilities | $41.6M | $95.1M | $74.6M | $79.9M |
| LT Operating Leases | $12.1M | $77.0M | $72.4M | $67.0M |
| Other LT Liab | $1.5M | $1.3M | $2.2M | $1.5M |
| Total Liabilities | $113.0M | $180.8M | $142.4M | $163.1M |
| Shareholders' Equity | $490.2M | $395.0M | $835.6M | $1.58B |
| Retained Earnings | $-383.8M | $-530.8M | $-754.6M | $-1.07B |
| AOCI | $-4.9M | $-552.0K | $-1.5M | $1.8M |
| Total L&E | $603.1M | $575.8M | $978.0M | $1.74B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-154.8M | $-147.0M | $-223.9M | $-311.4M |
| Non-Cash Adjustments | $32.5M | $31.5M | $73.1M | $42.7M |
| Working Capital Changes | $-30.8M | $12.6M | $-43.8M | $35.7M |
| Cash from Operations | $-153.1M | $-102.8M | $-194.5M | $-232.9M |
| Capital Expenditures | $2.8M | $34.5M | $12.8M | $1.4M |
| Cash from Investing | $20.5M | $139.9M | $-404.1M | $-521.1M |
| Cash from Financing | $153.0M | $4.2M | $608.9M | $990.7M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $20.4M | $41.3M | $10.3M | $236.8M |
| Beginning Cash | $54.1M | $74.5M | $115.8M | $126.0M |
| Ending Cash | $74.5M | $115.8M | $126.0M | $362.8M |
Frequently Asked Questions
How does Kymera Therapeutics, Inc. make money?
The company's financials indicate a single primary business segment driven by R&D expenditures ($316.6M) and general administrative costs ($68.2M), with revenue generated exclusively from research collaborations, licensing fees, or grant income totaling $39.2M in the latest period.
What are the main risks for KYMR?
The company faces substantial risk of failure in advancing its clinical pipeline, as evidenced by significant net losses increasing from -$154.8M in 2022 to -$311.4M in 2025. High operating expenses and a retained earnings deficit of -$1.07B indicate heavy reliance on external funding sources like the $990.7M cash flow from financing activities. Future revenue is uncertain as the current stream of $39.2M represents a decline from 2023's peak of $78.6M, suggesting potential instability in partnership deals.
What is KYMR's competitive advantage?
Kymera holds significant intellectual property rights regarding its unique approach to targeting intrinsically disordered proteins (IDPs), a biological class previously considered undruggable by traditional small molecules. The company benefits from a differentiated science platform that could unlock new therapeutic avenues for diseases currently lacking effective treatments. Strong cash reserves of $357M provide ample runway to advance multiple clinical candidates without immediate need for capital raising.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.